Search Results - I. Yu. Pirogova

  • Showing 1 - 12 results of 12
Refine Results
  1. 1

    Screening investigation of patients with diffuse liver diseases by I. Yu. Pirogova

    Published 2010-06-01

    Aim of investigation. To present data on screening investigation of patients at suspicion for diffuse liver disease, including series of routine methods specified by medical standards.Original positions. Article presents data on diagnostic accuracy, sensitivity, specificity of taken into account met...

    Full description

    Get full text
    Article
  2. 2

    Complex application of mathematical methods in diagnostics of diffuse liver diseases by I. Yu. Pirogova, S. A. Pyshkin, A. A. Bolotov

    Published 2011-02-01

    Aim of investigation. The standard of diffuse liver disease (DLD) diagnostics, allowing to determine etiology, stage of liver fibrosis (LF), histological activity index (HAI) is the liver biopsy (LB). At inaccessibility of LB for diagnostics, LF stage can be assessed by noninvasive methods based on...

    Full description

    Get full text
    Article
  3. 3

    Differentiated approach at the choice of chronic hepatitis C antiviral therapy mode (real clinical practice experience) by I. Yu. Pirogova, N. B. Kovaleva, E. P. Patlusov, E. S. Radchenko

    Published 2018-08-01

    Aim of the study. To estimate efficacy and safety of cepeginterferon-alpha 2b (cPEG-IFNα2b) and ribavirin combination for the treatment of chronic hepatitis C (CHC), to define necessity of IL-28V genetic polymorphism diagnostics, to estimate liver elastometry scores at the background of antiviral th...

    Full description

    Get full text
    Article
  4. 4

    Efficacy and Safety of Bicyclol Treatment for Non-Alcoholic Fatty Liver Disease: Results of a Cohort Study by I. Yu. Pirogova, S. V. Yakovleva, T. V. Neuymina, S. P. Sinitsyn, V. S. Chulkov, T. N. Shamaeva

    Published 2018-09-01

    Aim. This study is aimed at evaluating the efficacy and safety of Bicyclol administration in patients suffering from non-alcoholic fatty liver disease (NAFLD) («ZIGUN» research) by monitoring laboratory data and non-invasive methods of diagnosis of liver fibrosis and steatosis.Materials and methods....

    Full description

    Get full text
    Article
  5. 5

    Diagnostic options of non-invasive assessment of fibrosis at diffuse liver diseases by I. Yu. Pirogova, S. A. Pyshkin, Ye. V. Yefremova, A. N. Gorfinkel, S. G. Pogorelova, N. V. Abramovskaya

    Published 2009-08-01

    Aim of investigation. To study potentials of noninvasive methods application for assessment of liver fibrosis at screening diagnosis of patients with diffuse liver diseases.Material and methods. Overall 188 HCV RNApositive patients and 61 HBV DNA-positive were investigated. The stage of disease in a...

    Full description

    Get full text
    Article
  6. 6
  7. 7

    An Effect of Ursodeoxycholic Acid on Inflammation, Steatosis and Liver Fibrosis and Atherogenesis Factors in Patients with Non-Alcoholic Fatty Liver Disease: Results of the USPEH S... by M. V. Mayevskaya, M. Yu. Nadinskaia, V. D. Lunkov, I. Yu. Pirogova, E. V. Chesnokov, Kh. B. Kodzoeva, V. T. Ivashkin

    Published 2020-01-01

    Aim. To evaluate effects of ursodeoxycholic acid (UDCA) on inflammation, steatosis and liver fibrosis and atherogenesis factors in patients with non-alcoholic fatty liver disease (NAFLD).Materials and methods. The study included 139 patients with NAFLD who received 15 mg/kg of UDCA (Ursosan®) per da...

    Full description

    Get full text
    Article
  8. 8

    Outcomes of the toxic hepatites caused by alcohol surrogates by I. Yu. Pirogova, I. Yu. Ponomareva, S. P. Sinitsyn, Ye. P. Samokhina, A. S. Gorbunova, Ye. Yu. Startseva, V. S. Chulkov, T. F. Kondrat'yeva

    Published 2013-12-01

    Aim of investigation. To estimate outcomes of toxic hepatites (TH) after intake of alcohol surrogates («Mozhzhevelovy» spirit for external use) with development of original prognostic model of patients survival.Material and methods. Retrospective analysis of clinical and laboratory data and survival...

    Full description

    Get full text
    Article
  9. 9

    Antioxidants in the Treatment of Chronic Diffuse Liver Diseases (the Results of the “MAXAR” Observational Program) by M. V. Mayevskaya, V. T. Ivashkin, V. D. Lunkov, S. P. Kryzhanovskiy, I. Yu. Pirogova, Ch. S. Pavlov, M. S. Zharkova, A. G. Beniashvili, M. A. Morozova

    Published 2018-11-01

    In the Russian Federation, liver diseases are most frequently represented by two their nosological forms, i.e., nonalcoholic and alcoholic fatty liver disease (NAFLD and ALD). A successful management of such patients, along with improving the functional state of the liver, requires a careful analysi...

    Full description

    Get full text
    Article
  10. 10

    Treatment of end-stages of liver disease in outcome of persistent hepatitis C virus infection at deficiency of donor organs by Ye. N. German, M. V. Mayevskaya, O. I. Andreytseva, V. T. Ivashkin, A. V. Chzhao, A. G. Serova, G. V. Mikhaylovskaya, I. Yu. Pirogova

    Published 2011-03-01

    Aim of investigation. To study the role of serological markers of hepatitis B virus infection: antibodies to hepatitis B virus cor-antigen (anti-HВcor IgG) in progressing liver damage at patients with persistent hepatitis C virus infection.Material and methods. For the first time in the large group...

    Full description

    Get full text
    Article
  11. 11

    Case of acute drug-induced hepatitis after halothane anesthesia by I. Yu. Pirogova, Ye. V. Berestova, O. Yu. Bastrikov, Ye. B. Kovaleva, T. P. Petukhova, M. V. Guseva, I. A. Gubina, I. V. Rezepin, S. P. Sinitsyn

    Published 2013-05-01

    The aim of publication. To present the case of severe acute drug-induced hepatitis after halothane anesthesia in relation to significance of allergies history preoperative inquiry and assessment of medical management of patients, using modern prognostic scales.Key points. Biotransformation of volati...

    Full description

    Get full text
    Article
  12. 12